Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
1. A solid form comprising (a) 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one; and (b) a coformer selected from the group consisting of gentisic acid and nicotinamide.
2. The solid form of claim 1 , wherein the coformer is gentisic acid.
3. The solid form of claim 1 , wherein the coformer is nicotinamide.
4. The solid form of claim 1 , which is greater than 80% by weight of a crystal form.
5. The solid form of claim 4 , which is greater than 80% by weight of a cocrystal.
6. The solid form of claim 5 , which is greater than 90% by weight of a cocrystal.
7. The solid form of claim 6 , which is greater than 95% by weight of a crystal form.
8. The solid form of claim 7 , which contains less than 3% by weight of other solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
9. The solid form of claim 8 , further comprising amorphous 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
10. The solid form of claim 9 , which is greater than 99% by weight of a crystal form.
11. A pharmaceutical composition comprising the solid form of claim 1 , and a pharmaceutically acceptable excipient or carrier.
12. The pharmaceutical composition of claim 11 , which is a single unit dosage form.
13. The pharmaceutical composition of claim 12 , which is a tablet.
14. The pharmaceutical composition of claim 12 , which is a capsule.